Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities
Source abstract
Abstract
This present study carried out a systematic review and meta-analysis of peptide nanoparticles in diabetes management for improved patient outcomes from 2014 to 2024. Different electronic databases, including PubMed, Scopus, Web of Science, ResearchGate, Google Scholar, and the Cochrane Library, were searched for relevant literature using Medical Subject Headings (MeSH) and boolean operators. A total of 317 articles were obtained and include PUBMED (39), Scopus (215), ResearchGate (30), Google Scholar (25), and Cochrane Library (8). From these, 186 duplicate entries were eliminated, while 76 articles were dismissed for some reasons. After scanning the titles, abstracts, and contents of the remaining 55 articles for relevance, 22 articles were eliminated. After a full-text screening using inclusion/exclusion criteria, an additional 11 articles were discarded, while 4 were excluded during the data extraction phase. In the end, seven (7) publications were considered relevant based on the eligibility criteria, representing 2.22%. Results showed that sequential exclusion of the studies did not have a significant impact on the effects of peptide nanoparticles on glucose control, insulin delivery, bioavailability, efficacy, safety, and patient outcomes in diabetes management. Also, peptide nanoparticles had positive improvement on glycemic control, insulin levels, glycated hemoglobin (HbA1C) levels, and overall patient outcomes. The study concludes that peptide nanoparticles harbour the potential to improve diabetes management through enhanced glucose control, insulin delivery, and patient outcomes. However, there is a significant gap in knowledge. Further research is required to understand the long-term safety and efficacy of many of the enlisted nanoparticles. Additionally, future studies should explore a wider range of peptides and proteins for encapsulation, develop delivery systems for larger and conformationally diverse molecules, and improve the oral bioavailability of encapsulated therapeutics. Long-term clinical trials are needed to validate this approach in humans and elucidate the underlying mechanisms for optimal treatment design. If these knowledge gaps are addressed, peptide nanoparticles will unavoidably become a powerful tool for effective management of diabetes along with traditional methods.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Infant Nutrition and Health · Protein Hydrolysis and Bioactive Peptides
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. American Diabetes Association (ADA). (2024). In This Issue of Diabetes. Diabetes, 73. https://doi.org/10.2337/db24-ti0510.2337/db24-ti05 ↗
2. Ndjaboue R, Farhat I, Ferlatte CA, Ngueta G, Guay D, Delorme S, Witteman HO. Predictive models of diabetes complications: protocol for a scoping 2020.10.31219/osf.io/pnv25 ↗
3. World Health Organization (WHO). (2016). Global Report on Diabetes. Retrieved from https://iris.who.int/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1
4. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119. https://doi.org/10.1016/j.diabres.2021.109119.10.1016/j.diabres.2021.109119 ↗
5. Afaya RA, Bam V, Azongo TB, Afaya A. Knowledge of chronic complications of diabetes among persons living with type 2 diabetes mellitus in northern Ghana. PLoS ONE. 2020;15(10): e0241424. https://doi.org/10.1371/journal.pone.0241424.10.1371/journal.pone.0241424 ↗
6. Liu X, Yu C, Wang Y, Bi Y, Liu Y, Zhang ZJ. Trends in the incidence and mortality of diabetes in China from 1990 to 2017: a joinpoint and age-period-cohort analysis. Int J Environ Res Public Health. 2019;16(1):158.10.3390/ijerph16010158 ↗
7. Wang B, Fu Y, Tan X, et al. Assessing the impact of type 2 diabetes on mortality and life expectancy according to the number of risk factor targets achieved: an observational study. BMC Med. 2024;22:114. https://doi.org/10.1186/s12916-024-03343-w.10.1186/s12916-024-03343-w ↗
8. Sriram U, Selvaraj DH, Devarajan J. Outcomes of a digital intervention focusing on wearable technology and lifestyle modifications on persons with diabetes 2022.
9. Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018;6(1):P69-80. https://doi.org/10.1016/S2213-8587(17)30186-9.10.1016/S2213-8587(17)30186-9 ↗
10. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2023). Managing Diabetes. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes
11. Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY, Santini A. Nanoparticle delivery systems in the treatment of diabetes complications. Molecules. 2019;24(23):4209.10.3390/molecules24234209 ↗
12. Tiwari SS, Wadher SJ. Potential nanomaterials for the treatment and management of diabetes mellitus. In: Mane RS, Sharma RP, Kanakdande AP, editors. Nanomaterials for sustainable development. Singapore: Springer; 2023. https://doi.org/10.1007/978-981-99-1635-1_11.10.1007/978-981-99-1635-1_11 ↗
13. Samavati SS, Kashanian S, Derakhshankhah H, et al. Nanoparticle application in diabetes drug delivery. J Nanopart Res. 2022;24:178. https://doi.org/10.1007/s11051-022-05547-8.10.1007/s11051-022-05547-8 ↗
14. Crowther M, Lim W, Crowther MA. Systematic review and meta-analysis methodology. Blood. 2010;116(17):3140–6. https://doi.org/10.1182/blood-2010-05-280883.10.1182/blood-2010-05-280883 ↗
15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.10.1136/bmj.n71 ↗
16. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https://doi.org/10.1136/bmj.d5928.10.1136/bmj.d5928 ↗
17. Hoodin F, Weber S. A systematic review of psychosocial factors affecting survival after bone marrow transplantation. Psychosomatics. 2003;44(3):181–95.10.1176/appi.psy.44.3.181 ↗
18. Soudry-Kochavi L, Naraykin N, Di Paola R, Gugliandolo E, Peritore A, Cuzzocrea S, Ziv E, Nassar T, Benita S. Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles. Eur J Pharm Biopharm. 2018. https://doi.org/10.1016/j.ejpb.2018.10.013.10.1016/j.ejpb.2018.10.013 ↗
19. Pomposelli T, Wang P, Takeuchi K, Miyake K, Ariyoshi Y, Watanabe H, Chen X, Shimizu A, Robertson N, Yamada K, Moore A. Protection of pancreatic islets using theranostic silencing nanoparticles in a baboon model of islet transplantation. Diabetes. 2020;69(11):2414–22. https://doi.org/10.2337/db20-0517.10.2337/db20-0517 ↗
20. Ai T, Chen F, Zhou S, Zhang J, Zheng H, Zhou Y, Lin J. Magnetic bead-based serum peptidome profiling in patients with gestational diabetes mellitus. BioMed Res Int 2015.10.1155/2015/586309 ↗
21. Guo F, Zhang M, Gao Y, Zhu S, Chen S, Liu W, Zhong H, Liu J. Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation. Informa Healthcare USA Inc.; 2015. https://doi.org/10.3109/10717544.2015.1048489.10.3109/10717544.2015.1048489 ↗
22. Ji N, Hong Y, Gu Z, Cheng L, Li Z, Li C. Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. J Control Release. 2019;31(3):1–3. https://doi.org/10.1016/j.jconrel.2019.10.006.10.1016/j.jconrel.2019.10.006 ↗
23. Wang Q, Xue X, Liu Y, Han J, Zhai R, Zhao S, Liu Z. Exenatide thermosensitive gel nanoparticle nasal spray. Chin Pharm J. 2021;56(17):1406–13. https://doi.org/10.1166/cpj.2021.17.008.10.1166/cpj.2021.17.008 ↗
24. Burtea C, Laurent S, Crombez D, Delcambre S, Sermeus C, Millard I, Rorive S, Flamez D, Beckers MC, Salmon I, Vander Elst L, Eizirik DL, Muller RN. Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells. Contrast Media Mol Imaging. 2015;10:398–412.10.1002/cmmi.1641 ↗
25. Senduran N, Yadava HN, Vishwakarma VK, Bhatnagar P, Gupta P, Bhatia J, Dinda AK. Orally deliverable nanoformulation of liraglutide against type 2 diabetic rat model. J Drug Deliv Sci Technol. 2020;56: 101513. https://doi.org/10.1016/j.jddst.2020.101513.10.1016/j.jddst.2020.101513 ↗
26. Bhavsar J, Kasture K, Salvi BV, Shende P. Strategies for transportation of peptides across the skin for treatment of multiple diseases. Ther Deliv. 2024;1–24.10.1080/20415990.2024.2411943 ↗
27. Asaad GF, Doghish AS, Rashad AA, El-Dakroury WA. Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics. Naunyn-Schmiedeberg’s Arch Pharmacol. 2024;1–16.10.1007/s00210-024-03532-7 ↗
28. Mehrotra S, Bg PK, Nayak PG, Joseph A, Manikkath J. Recent progress in the oral delivery of therapeutic peptides and proteins: overview of pharmaceutical strategies to overcome absorption hurdles. Adv Pharm Bull. 2023;14(1):11.
29. Chen L, Long W, Luo J, Jiang M, Wang K. Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment. Int J Nanomed. 2021;16:1261–80. https://doi.org/10.2147/IJN.S283416.10.2147/IJN.S283416 ↗
30. Bao X, Qian K, Yao P. Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice. J Nanobiotechnol. 2020. https://doi.org/10.1186/s12951-020-00619-0.10.1186/s12951-020-00619-0 ↗
31. Lu W, Luo M, Fang X, et al. Discovery of metabolic biomarkers for gestational diabetes mellitus in a Chinese population. Nutr Metab. 2021. https://doi.org/10.1186/s12986-021-00606-8.10.1186/s12986-021-00606-8 ↗
32. Zhang Q, Li C, Du X, Zhong H, He Z, Hong P, Jing Z. High strength, tough and self-healing chitosan-based nanocomposite hydrogels based on the synergistic effects of hydrogen bond and coordination bond. J Polym Res. 2022;29(8):335.10.1007/s10965-022-03163-7 ↗
33. Sjöholm Å. Liraglutide therapy for Type 2 diabetes: overcoming unmet needs. Pharmaceuticals. 2010;3(3):764–81. https://doi.org/10.3390/ph3030764.10.3390/ph3030764 ↗
34. Zashikhina N, Sharoyko V, Antipchik M, Tarasenko I, Anufrikov Y, Lavrentieva A, Korzhikova-Vlakh E. Novel formulations of C-peptide with long-acting therapeutic potential for treatment of diabetic complications. Pharmaceutics. 2019;11(1):27.10.3390/pharmaceutics11010027 ↗
35. Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:20. https://doi.org/10.1186/s40824-019-0166-x.10.1186/s40824-019-0166-x ↗
36. Marinheiro D, Martel F, Ferreira BJML, Daniel-da-Silva AL. Silica-based nanomaterials for diabetes mellitus treatment. Bioengineering. 2023;10(1):40. https://doi.org/10.3390/bioengineering10010040.10.3390/bioengineering10010040 ↗
37. Ismail R, Csóka I. Novel strategies in the oral delivery of antidiabetic peptide drugs–Insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 2017;115:257–67.10.1016/j.ejpb.2017.03.015 ↗
38. Abeer MM, Rewatkar P, Qu Z, Talekar M, Kleitz F, Schmid R, Popat A. Silica nanoparticles: a promising platform for enhanced oral delivery of macromolecules. J Control Release. 2020;326:544–55.10.1016/j.jconrel.2020.07.021 ↗
39. Jing Z, Li Y, Ma Y, Zhang X, Liang X, Zhang X. Leverage biomaterials to modulate immunity for type 1 diabetes. Front Immunol. 2022;13: 997287.10.3389/fimmu.2022.997287 ↗
40. Malathi S, Nandhakumar P, Pandiyan V, Webster TJ, Balasubramanian S. Novel PLGA-based nanoparticles for the oral delivery of insulin. Int J Nanomed. 2015; 2207–2218.10.2147/IJN.S67947 ↗
41. Mura P, Maestrelli F, Cirri M, Mennini N. Multiple roles of chitosan in mucosal drug delivery: an updated review. Mar Drugs. 2022;20(5):335.10.3390/md20050335 ↗
42. Sarkar S, Das D, Dutta P, Kalita J, Wann SB, Manna P. Chitosan: A promising therapeutic agent and effective drug delivery system in managing diabetes mellitus. Carbohydr Polym. 2020;247: 116594.10.1016/j.carbpol.2020.116594 ↗
43. Wang J, Li B, Qiu L, et al. Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng. 2022. https://doi.org/10.1186/s13036-022-00298-5.10.1186/s13036-022-00298-5 ↗
44. Mishra V, Nayak P, Sharma M, Albutti A, Alwashmi AS, Aljasir MA, Tambuwala MM. Emerging treatment strategies for diabetes mellitus and associated complications: an update. Pharmaceutics. 2021;13(10):1568.10.3390/pharmaceutics13101568 ↗
45. Pérez-Ferreiro M, Abelairas A, Criado A, Gómez IJ, Mosquera J. Dendrimers: exploring their wide structural variety and applications. Polymers. 2023;15(22):4369.10.3390/polym15224369 ↗
46. Shaikh A, Kesharwani P, Gajbhiye V. Dendrimer as a momentous tool in tissue engineering and regenerative medicine. J Control Release. 2022;346:328–54.10.1016/j.jconrel.2022.04.008 ↗
47. Paul S, Sarkar I, Sarkar N, et al. Silver nanoparticles in diabetes mellitus: therapeutic potential and mechanistic insights. Bull Natl Res Centre. 2022. https://doi.org/10.1186/s42269-024-01182-6.10.1186/s42269-024-01182-6 ↗
48. Debele TA, Park Y. Application of nanoparticles: diagnosis, therapeutics, and delivery of insulin/anti-diabetic drugs to enhance the therapeutic efficacy of diabetes mellitus. Life. 2022;12(12):2078.10.3390/life12122078 ↗
49. Deng YD, Zhang XD, Yang XS, Huang ZL, Wei X, Yang XF, Liao WZ. Subacute toxicity of mesoporous silica nanoparticles to the intestinal tract and the underlying mechanism. J Hazard Mater. 2021;409: 124502.10.1016/j.jhazmat.2020.124502 ↗
50. Yang L, Patel KD, Rathnam C, Thangam R, Hou Y, Kang H, Lee KB. Harnessing the therapeutic potential of extracellular vesicles for biomedical applications using multifunctional magnetic nanomaterials. Small. 2022;18(13):2104783.10.1002/smll.202104783 ↗
51. Zhu Z, Garcia-Gancedo L, Flewitt AJ, Xie H, Moussy F, Milne WI. A critical review of glucose biosensors based on carbon nanomaterials: carbon nanotubes and graphene. Sensors. 2012;12(5):5996–6022. https://doi.org/10.3390/s120505996.10.3390/s120505996 ↗
52. Jana P, Dev A. Carbon quantum dots: a promising nanocarrier for bioimaging and drug delivery in cancer. Mater Today Commun. 2022;32: 104068.10.1016/j.mtcomm.2022.104068 ↗
53. Spicer CD, Jumeaux C, Gupta B, Stevens MM. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. Chem Soc Rev. 2018;47:3574–620. https://doi.org/10.1039/C7CS00877E.10.1039/C7CS00877E ↗
54. Sharma R, Borah SJ, Bhawna KS, Gupta A, Kumari V, Kumar R, Dubey KK, Kumar V. Emerging trends in nano-based antidiabetic therapeutics: a path to effective diabetes management. Mater Adv. 2023;4:3091–113. https://doi.org/10.1039/D3MA00159H.10.1039/D3MA00159H ↗
55. Wu Y, Angelova A. Recent uses of lipid nanoparticles, cell-penetrating and bioactive peptides for the development of brain-targeted nanomedicines against neurodegenerative disorders. Nanomaterials. 2023;13(23):3004. https://doi.org/10.3390/nano13233004.10.3390/nano13233004 ↗
56. Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–98.10.1111/jphp.13098 ↗
57. Prajapati A, Rana D, Rangra S, Jindal AB, Benival D. Current status of therapeutic peptides for the management of diabetes mellitus. Int J Pept Res Ther. 2024;30(2):13.10.1007/s10989-024-10590-1 ↗
58. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Fu C. Therapeutic peptides: current applications and future directions. Signal Transd Target Ther. 2022;7(1):48.10.1038/s41392-022-00904-4 ↗
59. Wang Y, Wang C, Li K, Song X, Yan X, Yu L, He Z. Recent advances of nanomedicine-based strategies in diabetes and complications management: diagnostics, monitoring, and therapeutics. J Control Release. 2021;330:618–40.10.1016/j.jconrel.2021.01.002 ↗
60. Wallis L, Kleynhans E, Toit TD, Gouws C, Steyn D, Steenekamp J, Hamman J. Novel non-invasive protein and peptide drug delivery approaches. Protein Peptide Lett. 2014;21(11):1087–101.10.2174/0929866521666140807112148 ↗
61. Wang XQ, Zhang Q. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur J Pharm Biopharm. 2012;82(2):219–29.10.1016/j.ejpb.2012.07.014 ↗
62. Kumar R, Islam T, Nurunnabi M. Mucoadhesive carriers for oral drug delivery. J Control Release. 2022;351:504–59.10.1016/j.jconrel.2022.09.024 ↗
63. Li Y, Zhang W, Zhao R, Zhang X. Advances in oral peptide drug nanoparticles for diabetes mellitus treatment. Bioact Mater. 2022. https://doi.org/10.1016/j.bioactmat.2022.02.025.10.1016/j.bioactmat.2022.02.025 ↗
64. Garbati P, Picco C, Magrassi R, Signorello P, Cacopardo L, Dalla Serra M, Viti F. Targeting the gut: a systematic review of specific drug nanocarriers. Pharmaceutics. 2024;16(3):431.10.3390/pharmaceutics16030431 ↗
65. Malhaire H, Gimel JC, Roger E, Benoît JP, Lagarce F. How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability? Adv Drug Deliv Rev. 2016;106:320–36.10.1016/j.addr.2016.03.011 ↗
66. Bendicho-Lavilla C, Seoane-Viaño I, Otero-Espinar FJ, Luzardo-Álvarez A. Fighting type 2 diabetes: formulation strategies for peptide-based therapeutics. Acta Pharmaceutica Sinica B. 2022;12(2):621–36.10.1016/j.apsb.2021.08.003 ↗
67. Klepach A, Tran H, Mohammed FA, ElSayed ME. Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery. Adv Drug Deliv Rev. 2022;186: 114322.10.1016/j.addr.2022.114322 ↗
68. Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 2020;157:2–36.10.1016/j.addr.2020.05.007 ↗
69. Chen J, Hu L, Yang G, Hu Q. Current therapeutic strategy in the nasal delivery of insulin: recent advances and future directions. Curr Pharm Biotechnol. 2018. https://doi.org/10.2174/1389201019666180619145429.10.2174/1389201019666180619145429 ↗
70. Behl CR, Pimplaskar HK, Sileno AP, Demeireles J, Romeo VD. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1–2):89–116.10.1016/S0169-409X(97)00063-X ↗
71. Kirkby M, Hutton ARJ, Donnelly RF. Microneedle Mediated transdermal delivery of protein, peptide and antibody based therapeutics: current status and future considerations. Pharm Res. 2020;37(6):117. https://doi.org/10.1007/s11095-020-02844-6.10.1007/s11095-020-02844-6 ↗
72. Jia B, Yang H, Han Y, Zhang Z, Qu X, Zhuang Y, Dai K. In vitro and in vivo studies of Zn-Mn biodegradable metals designed for orthopedic applications. Acta Biomater. 2020;108:358–72.10.1016/j.actbio.2020.03.009 ↗